Leerink
Coverage of Leerink in the Nexus archive.
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax's experimental drug obefazimod showed strong efficacy in a Phase 3 trial for ulcerative colitis, with over 50% of participants achieving clinical remission. However, the company's shares dropped after reporting cancer cases among treated patients, raising safety concerns.
- An unloved health-care stock gets a welcome nod in this AI-obsessed market
Leerink analysts upgraded J&J shares to a buy equivalent due to the company's new drugs. This upgrade is significant in the current AI-obsessed market. The move indicates confidence in J&J's pharmaceutical developments.